Efficacy of Lumateperone in depression associated with bipolar II disorder: a pooled analysis of late-phase clinical trials
Lumateperone 42 mg monotherapy or adjunctive therapy significantly improved symptoms of depression and disease severity in patients with bipolar II disorder across Phase 3 studies. Lumateperone was generally well tolerated. These results support lumateperone 42 mg to treat MDEs associated with bipolar II disorder.
Authors
- Susan G Kozauer
- Suresh Durgam (ORCID: https://orcid.org/0000-0001-6629-0619)
- Changzheng Chen (ORCID: https://orcid.org/0000-0002-7281-552X)
- Hassan Lakkis
- Roger S. McIntyre (ORCID: https://orcid.org/0000-0003-4733-2523)
Institutions
- Johnson & Johnson (United States) (US)
- University of Toronto (CA)
Publication Details
- Journal
- CNS Spectrums
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1017/s1092852925100564
- Primary Topic
- Bipolar Disorder and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00